Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McDermott

Showing results (381-390 of 567) with videos related to

Pageof 57
Sort By:
Emerging Infectious Diseases|June 8, 2007
International spread of multidrug-resistant Salmonella Schwarzengrund in food productsFrank M Aarestrup, Rene S Hendriksen, Jana Lockett, et al.
The Lancet. Oncology|April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 studyToni K Choueiri, David F McDermott, Jaime Merchan, et al.
ESMO Open|February 8, 2021
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma<sup>☆</sup>A A Tarhini, K Toor, K Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain MetastasesRavi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Foodborne Pathogens and Disease|July 5, 2005
Characterization of Salmonella Typhimurium of animal origin obtained from the National Antimicrobial Resistance Monitoring SystemS Zhao, P J Fedorka-Cray, S Friedman, et al.
Nature Medicine|April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisToni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Clinical and Experimental Immunology|September 5, 2012
Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patientsL R Coulthard, J Geiler, R J Mathews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell CarcinomaWenxin Xu, Maneka Puligandla, Judith Manola, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 12, 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell TherapyDavid J Einstein, Brian Halbert, Thomas Denize, et al.
Cancer|May 21, 2016
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapiesRana R McKay, Guillermo De Velasco, Lillian Werner, et al.
Pageof 57

Showing results (381-390 of 567) with videos related to

Sort By:
Pageof 57
Emerging Infectious Diseases|June 8, 2007
International spread of multidrug-resistant Salmonella Schwarzengrund in food productsFrank M Aarestrup, Rene S Hendriksen, Jana Lockett, et al.
The Lancet. Oncology|April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 studyToni K Choueiri, David F McDermott, Jaime Merchan, et al.
ESMO Open|February 8, 2021
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma<sup>☆</sup>A A Tarhini, K Toor, K Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain MetastasesRavi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Foodborne Pathogens and Disease|July 5, 2005
Characterization of Salmonella Typhimurium of animal origin obtained from the National Antimicrobial Resistance Monitoring SystemS Zhao, P J Fedorka-Cray, S Friedman, et al.
Nature Medicine|April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisToni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Clinical and Experimental Immunology|September 5, 2012
Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patientsL R Coulthard, J Geiler, R J Mathews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell CarcinomaWenxin Xu, Maneka Puligandla, Judith Manola, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 12, 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell TherapyDavid J Einstein, Brian Halbert, Thomas Denize, et al.
Cancer|May 21, 2016
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapiesRana R McKay, Guillermo De Velasco, Lillian Werner, et al.
Pageof 57